A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
Clinical trial NCT05285813 · TERMINATED
Trial details
- NCT number
- NCT05285813
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-06
- Primary completion
- 2026-05-15
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.